Moderna: What's Driving The Better Outlook?

Moderna raised its 2026 revenue growth forecast on Friday to 15% to 25%, compared with 2025. Its previous outlook called for growth of up to 10%. Stronger international COVID vaccine sales are driving the revenue improvement. Lower research spending is also helping earnings, while broader product diversification still has more to prove.

In its third quarter results, the company reported revenue of $1.3 billion, up 29% from a year earlier, and GAAP net income of $162 million. Financial amounts here are in U.S. dollars.

That gives investors two things to sort out: how much stronger the existing business has become, and how much future growth still depends on new products. Vaccine sales provide resources for development as customers pay. Turning that research into a broader, dependable business takes longer.

Moderna attributed the quarterly revenue increase primarily to international COVID vaccine sales, supported by deliveries under long term government partnerships. Those relationships include the United Kingdom, Canada and Australia.

Such agreements can make future business easier to plan for. But the delivery schedule still affects when sales appear in the results. On the earnings call, the chief financial officer said stronger revenue reflected demand, execution and shipment timing between the third and fourth quarters.

Suppose an order qualifies for revenue recognition when the customer receives it in September instead of October. That helps the third quarter even if the customer's annual purchases stay the same. Moderna also raised its full year forecast, which is more encouraging than a shift between quarters alone. Management did not provide a complete numerical breakdown of how much improvement came from each driver.

There are also two different kinds of diversification here. Selling into more countries can reduce dependence on one national market. Selling vaccines for other diseases can reduce dependence on COVID vaccination. The latest revenue improvement mainly shows progress on the first.

Research and development expense fell 27% to $583 million in the third quarter, compared with a year earlier. Management also lowered its full year research spending forecast to approximately $2.7 billion from $2.9 billion.

The company cited operating efficiencies and the completion or winding down of certain late stage infectious disease studies. Those savings have different implications. Finishing a study can lower spending because that work is done. Winding down a study can save money while changing the company's future opportunities. To judge the savings, we need to understand what work has finished and what work is being set aside.

The norovirus program illustrates the uncertainty around future research. An interim analysis, a check before a trial is complete, missed the statistical threshold for early success. Moderna now plans no additional group of participants this season and will discuss the path forward with health authorities. That interim result alone does not settle whether the vaccine works.

A smaller research bill helps current earnings. Its longer term value depends on what the remaining spending produces.

Moderna earned a profit in the third quarter but still reported a net loss for the first nine months of 2026. Neither figure, on its own, explains the change in its cash balance.

Cash, cash equivalents and investments rose to $8.0 billion at September 30 from $6.9 billion at June 30. The company said the increase primarily reflected approximately $2.6 billion of net proceeds from convertible financing and related transactions. Convertible notes are debt that can potentially become shares. They provide funding now, with repayment or possible dilution consequences later. Dilution means existing shareholders own a smaller percentage of the company when additional shares are issued.

Customer payments follow a different timetable. Most third quarter product sales remained uncollected at the end of September. A sale can count as revenue before the customer pays, so reported sales and cash receipts can differ. Moderna described this timing gap as a seasonal working capital effect.

The quarter also included a $950 million litigation settlement payment. That unusual outflow and the timing of customer collections make this a difficult period to use as a normal cash spending pace.

Borrowing gives Moderna more room to develop new products. To show it can consistently fund itself, the business would need to generate enough cash from operations to cover its investment needs across a full seasonal cycle. That makes customer collections and operating cash flow more useful tests than the headline cash balance.

Moderna already has a new product that can broaden its business beyond COVID. The FDA approved its flu vaccine, mFLUSIVA, on August 5 for adults aged 50 and older. For adults 65 and older, the approval uses an accelerated pathway that requires further study to verify clinical benefit.

Approval arrived after the annual contracting cycle, however. Moderna says its initial U.S. launch for the 2026 to 2027 flu season is limited. A company can have permission to sell a vaccine after customers have already made their purchasing decisions. Later buying cycles will provide a clearer test of demand.

The cancer opportunity is at an earlier commercial stage. Moderna says it and Merck are working toward regulatory submissions for intismeran autogene after reporting positive results from a late stage melanoma trial that tested the therapy with Merck's Keytruda. A launch remains subject to approval. Manufacturing, insurance coverage and adoption would then help determine how much of that clinical progress becomes a dependable business.

At Thursday's scheduled Analyst Day, useful detail would connect these development milestones to sales and cash generation. The broader test is straightforward: international orders that hold up after shipment timing effects pass, customer invoices turning into cash, and newer products contributing meaningful revenue. Those results would make the case for a more durable business.